RELENT - new approach for a safer and more effective treatment of patients who suffer from autoimmunity

The central question in RELENT is: Given the increasing number of treatment options becoming available, how can we determine which treatment is best for which patient? The new RELENT video gives an overview over the RELENT project, its content and vision from the perspective of the project coordinator, one of the RELENT scientists and a patient representative.

© RELENT

The RELENT consortium is working on chronic immune-mediated diseases, such as vasculitis, rheumatoid arthritis and inflammatory bowel disease. In all these diseases, the body’s own immune system attacks otherwise healthy tissue by mistake, leading to different pathologies. With our current knowledge, it is not possible to titrate the intensity of treatment to the individual need of the patient. RELENT aims to change this allowing for the first time the application of precision medicine to autoimmunity - a concept already well established in cancer treatment.

Link to the video: https://www.youtube.com/watch?v=hW42iSlapAg

Find out more: https://www.relent.eu/

Parole chiave

• Autoimmunity
• Vasculitis
• Rheumatoid Arthritis
• Inflammatory Bowel disease
• Immunosuppressors
• chronic autoimmune disease
• personalized Medicine

Paesi

Austria, Australia, Germany, France, Netherlands, Sweden, United Kingdom